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Abstract: In this minireview we focus on Hsp60 as a target for anticancer therapy. We discuss the new concepts of chaperonopathies and 
chaperonotherapy and present information on Hsp60 localization in the cell membrane of human tumor cells. We describe novel mecha-
nisms for Hsp60 reaching the extracellular environment that involve membrane-associated stages, as well as data on anti-Hsp60 antibod-
ies found in human sera, both in normal subjects and patients affected by autoimmune diseases. Finally, we discuss possible therapeutic 
applications of anti-Hsp60 antibodies in cancer treatment, evaluating also side effects on non-tumor cells. In conclusion, the way for in-
vestigating Hsp60-targeted anti-tumor therapy is open, at least for those tumors that express Hsp60 on its surface and/or secrete it outside 
the cell, as is the search for the molecular mechanisms involved in Hsp60 translocation from cytosol to cell membrane: elucidation of this 
mechanism will greatly facilitate the optimization of chaperonotherapy centered on Hsp60 with anti-tumor efficacy and minimal side ef-
fects. 
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CHAPERONES AND PATHOLOGY: THE CHAPERO-
NOPATHIES 
 Molecular chaperones (chaperones in short) constitute a large 
group of proteins with a variety of functions, some of which are 
crucial for organismal survival [1]. Chaperones have been described 
at first as players in a number of intracellular pathways pertaining 
to protein quality control such as protein folding, refolding and 
degradation after irreversible misfolding, and protein translocation 
but, as of late, other functions unrelated to protein homeostasis have 
been discovered, for instance apoptosis regulation and cell signaling 
[2]. Moreover, chaperones have been shown to participate in anti-
stress mechanism to protect cells and organisms against stressors 
and stress and its consequences [3, 4]. Finally and most interest-
ingly, has been the demonstration that chaperones have active par-
ticipation in extracellular events, as in cell-to-cell cross talk and 
immune system regulation [5-8]. 
 Nowadays, chaperones are seen as indispensable for cell and 
tissue homeostasis in all organisms, including humans [8, 9]. How-
ever, chaperones have also been recognized to play a pathogenic 
role in a number of diseases, now called chaperonopathies, because 
they are qualitatively and/or quantitatively altered or function to 
favor disease rather than the contrary [9, 10]. It is likely that aware-
ness of the role of chaperones in the etiopathogenesis of many dis-
eases will change the nosography in all health related disciplines, 
basic and applied. Moreover, the possibility to cure a chaperonopa-
thy caused by a defective or malfunctioning chaperone by tailored 
chaperonotherapy will contribute to improving life quality in a 
number of pathologic conditions [11, 12]. 
 In this article, we review recent findings pertaining to the po-
tential of the chaperone Hsp60, namely the Heat Shock Protein 60 
kDa, also called chaperonin 60 (Cpn60) or HSPD1 protein [13], in 
cancer management. 
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CHAPERONES IN THERAPEUTICS: CHAPERONOTHER-
APY
 The field of chaperonotherapy is mostly based on the cytopro-
tective effects that molecular chaperones have and that confer stress 
resistance to cells [11]. However, chaperonotherapy has in fact two 
opposite facets. That based on the cytoprotective action of chaper-
ones, just mentioned, and another, based on the fact that some 
chaperones can be pathogenic. In this latter case, a normal chaper-
one promotes disease rather than the contrary. In these conditions, 
chaperonopathies by mistake or collaborationism [10], the thera-
peutic action should be aimed at blocking or eliminating the mis-
taken chaperone. Illustrative examples of chaperonopathies by mis-
take or collaborationism are some types of tumors in which a chap-
erone, e.g., Hsp70 or Hsp90 (or both), is essential for tumor growth 
and dissemination. In these situations, antichaperone agents would 
be the choice for treatment. Along these lines, there are many re-
ports on chaperonotherapy at the experimental level and we cite 
here only very few of the many illustrative examples available: they 
pertain to Hsp90 inhibitors and to the administration of chaperones 
and to gene replacement for managing experimental conditions 
mimicking human cancer, autoimmune inflammation, and retinal 
and neurodegenerative disorders [14-21]. 
 In this work, we present the potential of Hsp60 for chaperono-
therapy but, before, we will discuss some critical aspects of this 
chaperonin’s biology in humans and the occurrence of anti-Hsp60 
antibodies. We will outline the travels of Hsp60 in the body and the 
impact of them on the immune system and the potential role of anti-
Hsp60 antibodies in therapeutics. 
HSP60 AND ITS ODYSSEY FROM THE INTRACELLULAR 
ENVIRONMENT TO DISTANT TARGETS 
 Most of the information available about functions of Hsp60 has 
been obtained by studies on its bacterial counterpart, GroEL [22, 
23]. Hsp60, like several other groups of chaperones, is evolutionar-
ily conserved [24, 25]. Both Hsp60 and GroEL are involved in pro-
tein folding, working in combination with a co-chaperone, Hsp10 
(GroES in bacteria) [26]. In eukaryotes, the Hsp60/Hsp10 molecu-
lar machinery is localized inside the mitochondria and is crucial for 
maintaining the mitochondrial respiratory-chain integrity and func-
tionality and, consequently, cell survival [27, 28]. This is valid not 
only in normal but also in tumor cells, in which Hsp60 levels are 
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frequently increased especially in extramitochondrial sites ((Fig. 1)
and Table 1) [29]. 
 In addition, during evolution Hsp60 acquired functions other 
than chaperoning in the classical sense of maintaining protein ho-
meostasis, such as regulation of glycogenesis and apoptosis [16, 30-
32]. For example, Hsp60 can exit mitochondria after cell stress and 
activate the caspase pathway by inducing caspase-3 cleavage. In 
contrast, when Hsp60 accumulates in the cytosol without mito-
chondrial release (a frequent condition during carcinogenesis) it has 
the opposite effect, i.e., it inhibits caspase-3 cleavage [31]. The 
latter may be a mechanism that operates for at least some tumors 
for cell proliferation during carcinogenesis. In this case, Hsp60 
seems to help the neoplasm rather than to protect the host and, 
therefore, these forms of cancer have been classified as chapero-
nopathies “by mistake” or “collaborationism” [10]. 
 In certain conditions, cytosolic Hsp60 translocates to cell mem-
brane [22, 23]. In order to explain this movement of the chaperonin, 
various molecular mechanisms, including epigenetic or post-
translational modifications, have been proposed, but none has yet 
been definitively established. Nonetheless, this translocation event 
can have important consequences because circulating antibodies 
could bind to the Hsp60 present on the cell membrane and thereby 
affect cell viability. In what pertains to tumor cells, the transloca-
tion event with localization of Hsp60 on the cell membrane can be 
considered a major tenet to develop novel anti-tumor therapy 
strategies for those tumors that do show this characteristic, mimick-
ing what happens with Hsp70 [5, 12]. 
 Hsp60 could be the target of specific monoclonal antibodies or 
antitumor vaccination protocols. However, it is not yet established 
for how long Hsp60 remains on the tumor-cell membrane. This 
time-period could, indeed, be very short because lipid rafts – spe-
cialized membrane microdomains – can remove and internalize 
membrane Hsp60 into multivesicular bodies, which in turn generate  
Table 1. Comparison of Subcellular Distribution of Hsp60 in 
Normal and Tumor cellsa
Cell TypeCell Compartment
Normal Tumor
Mitochondria +++ +++
Cytosol + +++
Membrane -/+ ++
Vesicles -/+ ++
Endoplasmic Reticulum / Golgi -/+ +
aSemiquantitative evaluation of Hsp60 in the compartments of normal and tumor cells, 
using transmission electron microscopy-immunogold with specific anti-Hsp60 antibod-
ies (for methodology see [33, 50], and references therein). The results are expressed in 
an arbitrary scale from - = Hsp60 undetectable, to +++ = Hsp60 abundantly present. 
The tumor cells studied were NCI-H292 (human mucoepidermoid bronchial carci-
noma), A549 (human lung adenocarcinoma) and K562 (human erythroleukemia) cell 
lines and were compared to 16HBE (human bronchial epithelium) and primary cultures 
of human dermal fibroblasts. Evaluation was made by two electron microscopists and 
the data presented reflect the mean of the results for each cell type and compartment. 
Personal data unpublished. 
Hsp60-loaded exosomes [33]. The latter are microvesicles involved 
in cell-to-cell cross talk and immune system regulation, as well as 
in tumor progression [34]. We have found that the tumor cells we 
tested actively secrete Hsp60 via exosomes (Fig. 2). In addition, 
Hsp60 can also be found in its free/soluble form in circulation [29], 
which suggests that the Golgi’s apparatus is also involved in its 
secretion from tumor cells. (Fig. 3) depicts a working model we 
have proposed for the “Odyssey” of Hsp60 when it moves from 
cytosol of tumor cells to extracellular space and then to circulation. 
Fig. (1). Hsp60 levels in tumor cells are frequently higher than in the normal tissue counterpart. 
The images show Hsp60 (brown color, darkest areas in black and white reproductions) detected by immunohistochemistry with specific anti-Hsp60 antibodies 
in carcinoma of prostate (a) and colon (b). Normal prostate tissue and colonic mucosa are shown in (c) and (d), respectively, in which Hsp60 is almost unde-
tectable (no brown color). Bar, 200 microns. For details about immunohistochemical detection of Hsp60 in tissues, see [44]. (The color version of the figure is 
available in the electronic copy of the article). 
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Some steps of these pathways are not yet fully elucidated and are 
currently under investigation. 
ANTI-HSP60 ANTIBODIES: DANGER OR SAFETY? 
 An increase in membrane Hsp60 and the presence of circulating 
Hsp60 are considered danger signals for the immune system in as 
much as they may lead to activation of immune cells [29, 35]. In-
formation about Hsp60 and activation of innate and adaptive im-
munities has been published and discussed elsewhere [35-37]. Here 
we concentrate on information about the specific humoral (anti-
body-mediated) immune response induced by Hsp60. 
 Human anti-Hsp60 antibodies have been found in normal popu-
lations [38] and in subjects with autoimmune diseases [39]. Hence, 
it has been postulated that an inappropriate immune reaction to 
Hsp60 contributes to autoimmune disease development [38]. 
 Due to the high degree of evolutionary conservation from mi-
crobial GroEL to human Hsp60, it is likely that some autoimmune 
conditions are initiated by bacterial infections that release the chap-
eronin into the circulation with the resulting production of anti-
Hsp60 antibodies. These antibacterial Hsp60 antibodies will cross-
react with the human chaperonin [35]. It is a difficult challenge to 
distinguish between the latter situation and those autoimmune con-
ditions primarily caused by the self, human Hsp60 with autoanti-
bodies produced against it ab initio. Whatever the mechanism that 
initiates anti-Hsp60 antibody production, one has to realize that 
these autoantibodies can cause not only autoimmune diseases but 
also they can participate in the destruction of tumor cells expressing 
Hsp60 on their surface [35]. 
 The antibody-antigen reaction can occur at the cell surface and 
also in the blood, generating tumor-cell lysis and immunocom-
Fig. (2). Hsp60 is released by tumor (H292, A549, and K562) but not by non-tumor (16BHE) cells into the extracellular environment via exosomes. 
Demonstration of Hsp60 by Western blotting in (a) immunoprecipitates from the conditioned media; (b) exosomes purified from the conditioned media; (c) 
whole-cell lysates. Each set of four Western Blot lanes represents four separate experiments. The data showed that while all cells had Hsp60 inside them (c)
and all released Hsp60 into the extracellular space (a), only tumor cells did it via exosomes (b). These results were confirmed in various ways, demonstrating 
that the process was an active secretion by healthy, viable, tumor cells, excluding passive release by dead and disrupted or damaged cells [33]. Reproduced, 
modified with permission from reference [33]. 
Fig. (3). Itineraries of Hsp60 in tumor cells. 
This figure summarizes, schematically, the conclusions derived from experimental observations, focusing on the various locations demonstrated for Hsp60 in 
cells. Hsp60 (black dots) in normal cells localizes mainly in mitochondria but in tumor cells it is found also in the cytoplasm and the cell membrane. In it, lipid 
rafts internalize Hsp60 toward multivesicular bodies (MVB) from where it is secreted via exosomes. Other data suggest that the Golgi may also participate in 
Hsp60 secretion (under investigation). Details are still missing for some of the intermediary steps, as illustrated by questions marks.
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plexes, respectively [35]. In turn, the former induces cell death, 
while the latter can lead to the formation of immunoprecipitates in 
the renal glomeruli for instance [35]. We have previously postu-
lated that if Hsp60 occurs on the surface of malignant cells, as al-
ready ascertained for some types of cancer, anti-Hsp60 antibodies 
have the potential ability to destroy the tumor [29, 35, 40]. Our 
hypothesis has been recently supported by observations on multiple 
myelomas [41]. It was reported that immunoglobulins (Ig) from 
myeloma patients after allogenic stem-cell transplantation recog-
nized Hsp60 aberrantly displayed on the surface of primary mye-
loma cells, whereas Ig from a control group of healthy donors did 
not. The authors confirmed that Hsp60 becomes accessible to the 
immune system after aberrant membrane exposure and, naturally, 
postulated that a humoral anti-chaperonin response may contribute 
to the more favorable prognosis shown by these patients after trans-
plantation. 
POSSIBLE APPLICATIONS OF, AND CAUTIONARY 
COMMENTS ON, HSP60-TARGETED ANTICANCER 
THERAPY
 The few publications discussed above on involvement of Hsp60 
in human carcinogenesis constitute a minimal but representative 
sample of what has been published on this matter and we refer to 
other reviews for a more comprehensive account [29, 36, 40, 42]. 
The conclusion is that information in the literature from our labora-
tories and those of others unmistakably justifies considering Hsp60 
among candidates for anti-cancer immunotherapy. 
 Hsp60 is increased in many forms of cancers, although in others 
its levels decrease [29]. When increased, Hsp60 may localize in the 
tumor-cell membrane as Hsp70 [43]. When exposed on the cell 
membrane, Hsps become accessible to circulating anti-Hsp antibod-
ies [41]. The presence of Hsp60 on the cell surface offers practical 
advantages in medicine. For example, from the diagnostic stand-
point, immunofluorescence and immunocyto- and immunohisto-
chemistry with the proper antibodies are useful methods for the 
pathologist to detect Hsp60 on the cell surface [44]. In addition, 
some studies open the possibility for exploring the use of either free 
or exosome-carried Hsp60 for vaccination against cancer [45, 46]. 
 If Hsp60 favors cancer growth, chaperonotherapy will consist 
of blocking the chaperonin by whatever method works without 
serious side effects. If the chaperonin offers a target on the tumor-
cell surface for specific antibodies that could initiate cell lysis, the 
use of these antibodies should then be part of anti-tumor chaperono-
therapy. In any case, it is obvious that the road to the development 
of antitumor strategies and reagents centered on Hsp60 is open and 
very inviting. 
 However, the probability of unwanted side effects of this form 
of therapy must be taken into consideration. Physical and mechani-
cal stress, as well as aging, may cause Hsp60 dislocation onto the 
cell membrane. For example, hypertension can induce Hsp60 expo-
sure on the surface of endothelial cells [47]. Other cells in which 
Hsp60 has been localized onto the plasma membrane are cardio-
myocytes during heart failure [48] and senescent platelets [49]. 
Importantly, a small quantity of membrane Hsp60 has been found 
Fig. (4). Benefits and possible risks of antitumor therapy by anti-Hsp60 antibodies. 
Anti-Hsp60 antibodies are potentially able to destroy tumor cells that present aberrant Hsp60 on the cell membrane and this offers an opportunity for develop-
ing anti-cancer immunotherapy centered on the chaperonin. However, other cytotypes (e.g., endothelial cells, cardiomyocytes, and platelets), not just tumor 
cells, in certain conditions may also expose Hsp60 on the cell membrane, a situation that would put non-tumor cells at risk of lysis induced by anti-Hsp60 
antibodies. Evaluation of this risk and the possible advantages of Hsp60 chaperonotherapy should be preferred objectives of cancer research in the upcoming 
years in order to prepare the road for clinical trials. 
456    Current Pharmaceutical Design, 2013, Vol. 19, No. 3 Cappello et al. 
also in normal mammal cells, including human fibroblasts [50]. 
Hence, cytotoxicity caused by anti-Hsp60 antibodies can potentially 
affect non-tumor but altered, and even normal, cells in addition to 
the cancer cells and, thus, generate severe adverse complications 
(Fig. 4). In addition, the presence of circulating Hsp60 may deter-
mine the formation of immunocomplexes that might deposit in the 
glomerular membrane, generating glomerulonephritis. 
 Another potential drawback of anti-Hsp60 antibodies as anti-
tumor agents is that internalization of Hsp60 via the lipid rafts 
pathway may occur at a rapid rate, reducing drastically the time of 
Hsp60 availability on the tumor cell membrane and, thus, limiting 
the efficacy of anti-Hsp60 immunotherapy. Another inconveniency 
to explore is that the removal of tumor cells exposing Hsp60 on 
their cell membrane could lead to a selection of more aggressive 
clones of tumor cells without Hsp60 on their surface. 
 In conclusion, Hsp60 has the potential to become a good target 
for a novel anti-cancer chaperonotherapy, at least in tumor cells that 
express this protein on their surface. However, it is crucial to obtain 
more information about the molecular mechanisms underlying the 
translocation of Hsp60 to the cell membrane. This is necessary for 
developing means to amplify outer-membrane localization, selec-
tively, in tumor cells and to ensure that the chaperonin remains 
accessible to antibodies long enough so they can react with it and 
trigger cell damage. 
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